Pre-Test Targeting EGFR Exon-20 Insertion Mutations in Non-Small Cell Lung Cancer Pre-Test Which of the following statements is TRUE regarding PCR-based molecular testing in EGFR exon 20 insertion? Exon 20 insertions can be detected with a selectivity of 0.01% and sensitivity as low as a single copy. Nearly 60% of patients remain untested for EGFR mutations. NCCN guidelines recommend against liquid biopsy. The specific sequence of EGFR ex20ins mutations is required. Unsure Updated CHRYSALIS data presented at the European Lung Cancer Congress in April 2023, which of the following agents was shown to have a median OS of 23 months and an ORR of 37% in patients with EGFR ex20ins-positive NSCLC after progression on platinum-based chemotherapy? Amivantamab Mobocertinib Osimertinib Poziotinib Unsure Which of the following is the most common grade 3-4 adverse event associated with EGFR exon-20 tyrosine kinase inhibitors treatment for NSCLC? Diarrhea Hypoalbuminemia Infusion-related reactions QTc prolongation Unsure Please rate your ability to distinguish among newer therapeutic options for the management of EGFR ex20ins-positive NSCLC. Excellent Very Good Good Fair Poor
